Want to see FR:ALTHX full AI Analyst Report?
ALTHX Stock Chart & Stats
€3.97
€0.14(3.53%)
At close: 4:00 PM EDT
€3.97
€0.14(3.53%)
Day’s Range― - ―
52-Week Range€1.49 - €5.10
Previous CloseN/A
Volume173.21K
Average Volume (3M)55.60K
Market Cap
€45.62M
Enterprise Value€33.30M
Total Cash (Recent Filing)€17.45M
Total Debt (Recent Filing)€2.59M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
May 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding14,472,778
10 Day Avg. Volume31,876
30 Day Avg. Volume55,604
Financial Highlights & Ratios
PEG Ratio-2.04
Price to Book (P/B)14.83
Price to Sales (P/S)0.00
P/FCF Ratio-31.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.79
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderated DebtDebt has moderated from prior peaks and remained around €2.9m recently, which somewhat reduces leverage pressure compared with earlier periods. This improvement does not remove balance-sheet risk, but it may provide modestly greater financial flexibility while the company advances its clinical pipeline.
Improving Cash-Burn TrendThe reduced magnitude of cash burn in 2024 and 2025 versus 2023 indicates some progress in controlling cash outflows. Although cash generation remains negative, a better burn trajectory can extend operating runway and improve the efficiency of funding required for ongoing development activities.
Equity RecoveryShareholder equity returning to positive territory in 2025 represents a balance-sheet improvement after the negative position recorded in 2024. While this recovery may reflect financing or accumulated-loss dynamics rather than operating strength, it nevertheless reduces the immediate severity of balance-sheet impairment.
Bears Say
Zero RevenueThe complete revenue drop to zero in 2025 highlights substantial commercialization and execution risk for a clinical-stage company. Without recurring product revenue, Theranexus has limited internal funding capacity and remains dependent on successfully advancing programs or securing external capital.
Persistent LossesPersistent losses and deeply negative EBIT and EBITDA show that the current business model has not yet reached operating profitability. Continued deficits can consume capital needed for clinical development, increase reliance on financing, and make future earnings power highly dependent on pipeline execution.
Negative Cash GenerationConsistently negative operating and free cash flow means the company does not currently fund its activities from internally generated cash. This structural cash deficit increases dependence on external financing and exposes shareholders to potential dilution or funding constraints during development.
Theranexus SA News
ALTHX FAQ
What was Theranexus SA’s price range in the past 12 months?
Theranexus SA lowest stock price was €1.49 and its highest was €5.10 in the past 12 months.
What is Theranexus SA’s market cap?
Theranexus SA’s market cap is €45.62M.
When is Theranexus SA’s upcoming earnings report date?
Theranexus SA’s upcoming earnings report date is May 04, 2027 which is in 191 days.
How were Theranexus SA’s earnings last quarter?
Theranexus SA released its earnings results on Sep 24, 2026. The company reported -€0.007 earnings per share for the quarter.
Is Theranexus SA overvalued?
According to Wall Street analysts Theranexus SA’s price is currently Overvalued.
Does Theranexus SA pay dividends?
Theranexus SA does not currently pay dividends.
What is Theranexus SA’s EPS estimate?
Theranexus SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Theranexus SA have?
Theranexus SA has 14,472,778 shares outstanding.
What happened to Theranexus SA’s price movement after its last earnings report?
Theranexus SA reported an EPS of -€0.007 in its last earnings report. Following the earnings report the stock price went up 1.786%.
Which hedge fund is a major shareholder of Theranexus SA?
Currently, no hedge funds are holding shares in FR:ALTHX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theranexus SA
Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluation for conditions related to sleep and wake cycles. Furthermore, they are developing THN201 to target neurocognitive challenges associated with Alzheimer's disease, and THN101 for the management of neuropathic discomfort. This company commenced operations in 2013 and is situated in Lyon, France.
Technical Analysis
GenSight Biologics SA
―
AB Science SA
―
Sensorion SAS
―
Intrasense SA
―
MedinCell SA
―